The efficacy and safety of ticagrelor vs. clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO). The aim of this study was to assess the longterm cost-effectiveness of treating ACS patients for 12 months with ticagrelor compared with generic clopidogrel.
Introduction
In patients who have acute coronary syndromes (ACS) with or without ST-segment elevation, the current clinical practice guidelines recommend dual antiplatelet treatment with aspirin [acetylsalicylic acid (ASA)] and clopidogrel. 1 -3 The PLATelet inhibition and patient Outcomes trial (PLATO) recently showed that in patients with ACS, treatment with ticagrelor when compared with clopidogrel significantly reduced the rate of the composite endpoint of death from vascular causes, myocardial infarction (MI), or stroke without an increase in the rate of overall major bleeding. 4 A comprehensive cost study based on PLATO reported that 12-month treatment with ticagrelor was associated with a reduction in health-care costs compared with clopidogrel treatment when excluding study drugs. 5 In order to prioritize treatments among scarce health-care resources, the long-term costs and health outcomes of different treatment strategies need to be assessed and compared. 6 In this study, we synthesize the risk of cardiovascular events, costs, and quality-of-life data from the PLATO study with drug costs and long-term extrapolation data in order to determine the long-term cost-effectiveness of treating ACS patients for 12 months with ticagrelor according to the European label.
Methods

Overview of cost-effectiveness
The treatment strategies under investigation are ticagrelor in addition to ASA and clopidogrel in addition to ASA for a 12-month duration according to the PLATO study (NCT00391872), of which the design 7 and clinical results 4, 8 have been extensively reported. In brief, the PLATO trial randomized 18 624 patients with ST-segment elevation or non-ST-segment elevation ACS, with onset during the previous 24 h to ticagrelor or clopidogrel as soon as possible after admission. 7 The key clinical findings from PLATO were a reduction in the rate of the composite endpoint of death from vascular causes, MI, or stroke [hazard ratio (HR) ¼ 0.84; 95% confidence interval (CI): 0.77 -0.92], and also a reduction in death from vascular causes (HR ¼ 0.79; 95% CI: 0.69-0.91) without an increase in the rate of overall PLATO-defined major bleeding (HR ¼ 1.04; 95% CI: 0.95-1.13). 4 In Europe, ticagrelor is indicated for the prevention of atherothrombotic events in adult patients with ACS [unstable angina, non-ST-elevation MI (NSTEMI) or ST-elevation MI (STEMI)], including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting. 9 Therefore, the base-case analysis was carried out on the full ACS population. The analysis was undertaken from a health-care perspective. In some jurisdictions, a societal perspective is preferred, but in this particular application, the difference between a societal and a health-care perspective is likely to be small. Costs and life table data required for extrapolation were based on Swedish sources. Costs are expressed in Euros (E) at 2010 prices and were, when required, converted to Euros using the average exchange rate in 2010 according to the European Central Bank (E1 ¼ 9.5373 Swedish kronor). 10 Health outcomes were estimated in terms of life expectancy and quality-adjusted life years (QALYs). Costs and health outcomes were discounted by 3.0% per annum. A two-part cost-effectiveness model comprising a short-term decision tree and a long-term Markov structure was utilized to estimate long-term costs and health outcomes (Figure 1) . The aim of the modelling exercise was to adhere closely to the PLATO study and the model structure is based on the key clinical outcomes of PLATO. Data from PLATO were used to estimate rates of cardiovascular events, health-care costs, and health-related quality of life for the 12 months of therapy. Although these estimates were incorporated into the first part of the cost-effectiveness model (decision tree in Figure 1 ), the first year of the analysis is not regarded as a model as it is based solely on randomized data from PLATO. For Year 2 and onwards (Markov model in Figure 1) , necessary assumptions and external data sources were utilized to extrapolate quality-adjusted survival and cost conditional on whether a non-fatal MI, a non-fatal stroke, or no MI or stroke occurred during the 12 months of therapy. Further details are available in the Supplementary material online. Figure 1 Model structure. Markov model transitions in figure: (1) risk of non-fatal myocardial infarction for patients with no myocardial infarction (MI) or stroke in the PLATO study. (2) Risk of non-fatal stroke for patients with no MI or stroke in the PLATO study. (3) Mortality risk for patients with no MI or stroke in the PLATO study. (4) Mortality risk at the first year after a non-fatal myocardial infarction. (5) Mortality risk at the first year after a non-fatal stroke. (6) Mortality risk at second and subsequent years after a non-fatal myocardial infarction. (7) Mortality risk at second and subsequent years after a non-fatal stroke.
Cost-effectiveness of treating acute coronary Event risks, costs, and quality of life from the PLATO study
The risk of the following clinical pathways, by treatment strategy, was estimated for the 12 months of therapy: a non-fatal MI occurring before a potential non-fatal stroke with no subsequent fatal event; a non-fatal stroke occurring before any potential non-fatal MI with no subsequent fatal event; death occurring at any point in the study follow-up; no further event, which is one minus the combined risk of the other three clinical pathways. Survival analysis 11 was employed to determine the risk of events, and the results of this analysis were incorporated into the model. 12 For selected subgroups, survival models were run to estimate different baseline event rates (clopidogrel group) associated with each subgroup. Based on the fact that there was no statistically significant interaction for the primary endpoint between treatment and the final index hospitalization diagnosis (P ¼ 0.41), between treatment and medical history of diabetes mellitus (P ¼ 0.49), and between treatment and planned treatment approach (P ¼ 0.88), the HRs for the overall population were used to generate the event rates for ticagrelor-treated patients. 4 The importance of this assumption for the final results was investigated in alternative scenarios. The estimated risk of all-cause death for all ACS patients while on therapy was 0.046 and 0.059 for ticagrelor-and clopidogrel-treated patients, respectively. The corresponding risk of the MI clinical pathway was 0.050 and 0.058 for ticagrelor-and clopidogrel-treated patients, respectively. The risk of the stroke clinical pathway was 0.010 for ticagrelor-treated patients and 0.009 for clopidogrel-treated patients. The cost estimates for the 12 months of therapy were based on the resource-use data collected in PLATO. Days on study drug, bed days due to hospitalizations, investigations, interventions, blood products and re-operations due to bleeding were recorded in the trial. The total health-care costs per patient, calculated by multiplying resource use by unit costs based on a Swedish setting, were used to estimate the mean per-patient health-care costs for each treatment group. A cost of generic clopidogrel (E0.06 per day, lowest available price in July 2011) and ticagrelor (E2.21 per day, reimbursed price in Sweden) was applied. In the trial-based cost analysis, the daily drug price was multiplied by the number of days patients were on the study drug. In order not to underestimate drug costs with ticagrelor in the cost-effectiveness analysis, the cost of study drugs was entered as a separate parameter and applied as long as patients remained alive during the 12 months of therapy. Due to administrative censoring (patients were followed until 6, 9 or 12 months when the pre-specified number of endpoints had occurred in the study), patients eligible for 12 months of follow-up (randomized before 18 January 2008) were included in the analysis of 12-month costs. The results showed that the mean per patient cumulative health-care cost at 12 months were E96 (95% CI: 2360 to 553, P ¼ 0.679) higher with ticagrelor-treated patients compared with clopidogrel-treated patients ( Table 1) . As expected, drug costs were higher with the ticagrelor strategy (mean difference ¼ 590; 95% CI: 582 to 598, P , 0.001). Non-drug health-care costs were numerically lower with the ticagrelor strategy, mainly due to the reduced number of bed days and interventions. For reasons of power, caution is warranted in the interpretation of P-values in the analysis of costs. Although not statistically significant, the results indicate that ticagrelor treatment is associated with an increase in health-care costs when compared with clopidogrel treatment; a trend evident in most of the analysed subgroups ( Table 1) Unit costs to value resource use based on a Swedish setting (see Supplementary material online, Table S5 ) and detailed resource use for all PLATO patients (see Supplementary material online, Table S8 ) are available. Note that N is lower than 18 624 patients enrolled in PLATO as patients eligible for 12 months of follow-up were analysed due to administrative censoring. Patients eligible for 12-month follow-up had similar characteristics to those not eligible for 12-month follow-up (see Supplementary material online, Table  S7 ). The mean difference in health-care costs using the full sample (corresponding to the average length of follow-up in the trial rather than 12 months treatment) was 116 (95% CI: 2224 to 455).
A similar approach to the cost analysis was used to estimate QALYs for the 12 months of therapy. The QALY estimates were based on EQ-5D 13 data collected within the PLATO study. EQ-5D was distributed in the index period and at 6 and 12 months. At each point of measurement, a QALY weight was derived applying the commonly used UK tariff. 13 A QALY estimate was calculated for each patient in the PLATO study who had a planned follow-up of 12 months (randomized before 18 January 2008). For patients alive at the end of the study and with all three EQ-5D measurements, the area under the curve was calculated assuming a linear relationship between QALY weight measurements at the index period and at 6 and 12 months. For patients who died in the study, the last QALY weight estimate was carried forward until the date of death in order to calculate the area under the curve. Overall, the estimated mean QALYs were similar between the treatment groups (ticagrelor 0.846 vs. clopidogrel 0.840, mean difference ¼ 0.006, 95% CI: 20.016 to 0.004).
Long-term extrapolation
In order to estimate long-term cost-effectiveness, quality-adjusted survival and costs were estimated conditional on whether a non-fatal MI, a non-fatal stroke, or no MI or stroke occurred during the 12 months of therapy using a Markov model. No treatment effect was incorporated in the Markov model as patients are no longer on the study medications; hence, the Markov model is identical for ticagrelor-and clopidogrel-treated patients. For patients surviving and not suffering a non-fatal MI or stroke during the 12 months of therapy, the annual risks of non-fatal MI and non-fatal stroke (transitions 1 and 2 in Figure 1 ) were estimated by extrapolating out the observed hazard function of clopidogrel-treated patients in PLATO beyond 1 year of follow-up. The annual mortality risk (transition 3 in Figure 1 ) in the no event state was estimated using age-specific mortality rates from Swedish life tables 14 to which an HR based on data from a Swedish MI registry is applied. 15 Similarly, survival after non-fatal events was modelled by estimating the HR corresponding to the increased hazard of death following an MI or stroke relative to standard mortality rates from life tables. Different estimates were applied the first year after a non-fatal event [non-fatal MI state (transition 4 in Figure 1 ) and non-fatal stroke state (transition 5 in Figure 1 )] when compared with the second year onwards [post-MI state (transition 6 in Figure 1 ) and post-stroke state (transition 7 in Figure 1) ]. These data are summarized in Table 2 .
For the purpose of estimating long-term costs, each state in the Markov model was assigned a cost estimate. Further analyses of the PLATO data were performed to estimate an annual cost associated with the no event state. The costs associated with a non-fatal event in the Markov model (non-fatal MI and non-fatal stroke states the first year, and the post-MI and post-stroke states the second year and onwards) were derived from the literature ( Table 2) .
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Regarding long-term QALYs, the QALY estimate for patients without an event in the PLATO study was applied in the no event state. The mean estimate of ticagrelor-and clopidogrel-treated patients was applied for patients aged ,70 years. As patients grow older in the model, a proportional decrement due to age was applied. 17 For the non-fatal MI, non-fatal stroke, post-MI, and poststroke states, the decrements associated with the non-fatal MI and non-fatal stroke clinical pathways in the PLATO study were applied. The decrements were subtracted from the QALY estimate applied in the no event state in the model. The QALY estimates for the longterm extrapolation are summarized in Table 2 .
Analysis
Costs and QALYs were calculated over a lifetime time horizon and are presented as mean outcomes per patient. The estimated mean costs and QALYs were combined into an incremental cost-effectiveness ratio (ICER) defined as:
where C is the estimated mean cost, Q the estimated mean QALYs, and the treatment strategies are indexed 1 for ticagrelor and 0 for clopidogrel. Cost-effectiveness of treating acute coronary Uncertainty in the estimated ICERs due to sampling uncertainty in the estimated input parameter values was evaluated by employing probabilistic sensitivity analysis. 19 In the probabilistic analysis, simulation was employed to propagate the uncertainty in single-model inputs through the model so that the uncertainty in the costeffectiveness results indicates the uncertainty in the decision to implement a treatment strategy rather than the uncertainty surrounding single model inputs. 19 The probability of ticagrelor being cost-effective at different levels of willingness to pay, or threshold values, for a QALY was also assessed. 20 Several alternative scenarios were analysed to assess uncertainty in the cost-effectiveness results related to model assumptions and data inputs that are not associated with sampling uncertainty. The patient characteristics in the base-case analysis were as observed in the PLATO study in which the clinical and economic evidence were generated. 4 Hence, the base-case analysis was based on the mean age (62 years) and the proportion of women (28.4%) enrolled in the PLATO study. It has been shown that 79% of the patients in Swedish clinical practice who were hospitalized with an index diagnosis of ACS in 2007 met the inclusion criteria in the PLATO study. 21 The impact of age and gender on the cost-effectiveness results was investigated in alternative scenarios. Tentative analyses of some key subgroups (STEMI, NSTEMI, unstable angina, intent for invasive management, and diabetes) were also performed in order to investigate the robustness of the cost-effectiveness results across a broad spectrum of ACS patients. All statistical analyses were performed using Stata version 7 (Stata Statistical Software: Release 7.0. College Station, TX, USA: Stata Corporation). The decision-analytic model was programmed and analysed in Microsoft w Excel (Microsoft Corporation, Redmond, Washington, DC, USA).
Results
Base-case analysis
The ticagrelor strategy was associated with a QALY gain of 0.1316 at an incremental cost of E362, yielding a cost per QALY gained of E2753 when compared with the strategy of generic clopidogrel ( Table 3 ). The cost per life year gained was E2372. The difference in total costs at different time horizons is presented in Figure 2 . The cost-effectiveness model provides a higher incremental cost with ticagrelor at 12 months compared with the trial-based analysis presented in Table 1 seen in Figure 3 that treating ACS patients for 12 months with ticagrelor is associated with a gain in QALYs at an incremental cost in the majority of simulations. The probability of ticagrelor being cost-effective for different willingness to pay, or threshold values, of a QALY is presented in the cost-effectiveness acceptability curves in Figure 4 . Applying conventional threshold values for a QALY, the probability of ticagrelor being cost-effective appears high. Although minor variations in the estimated ICERs can be observed, the cost-effectiveness results appear consistent across the investigated subgroups ( Table 3) . Similar to the base-case analysis, the probability of the ticagrelor strategy being cost-effective is high in the investigated subgroups (Figure 4) . The results of analysing men and women separately at different ages showed that age and gender were not heavily influencing the cost-effectiveness results (see Supplementary material online, Table S23 ).
Sensitivity scenarios
The sensitivity analyses indicate that the results of the base-case analysis are robust to plausible changes in input parameters. Table S25 -S28) . Finally, allowing the treatment effect (including event rates, costs, and quality of life) to vary in the analysed subgroups did not alter the conclusions of the base-case analysis (see Supplementary material online, Table  S29 ). The highest cost per QALY with ticagrelor was E6400 (unstable angina) and the lowest E102 (STEMI).
Discussion
The results of the cost-effectiveness analysis show that treatment with ticagrelor is associated with a cost per QALY of E2800 when compared with generic clopidogrel. This finding was consistent across major subgroups, indicating that treating ACS patients with ticagrelor compared with generic clopidogrel will improve quality-adjusted survival at a cost below generally acceptable thresholds for cost-effectiveness.
Although necessary assumptions and external data sources are inevitably employed to estimate long-term cost-effectiveness, the results are primarily driven by the clinical event rates observed in PLATO during the 12 months of therapy. In particular, the reduction in mortality is a key parameter. The long-term quality-adjusted survival in the larger proportion of patients alive at the end of 12-month treatment with ticagrelor when compared with clopidogrel is the major contributor to the estimated gain in QALYs with ticagrelor treatment.
In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38), it was reported that prasugrel is cost-effective compared with clopidogrel in ACS patients undergoing PCI. 22 In TRITON-TIMI 38, the majority of the estimated gain in life years with prasugrel compared with clopidogrel (0.074 out of the total 0.102 estimated gain in life years) was accrued due to a reduction in MIs. In the present study, the reduction in MIs with ticagrelor treatment compared with clopidogrel was not the major contributor to the long-term gain in life years (and QALYs). Rather, the majority of the gain in life years and QALYs was due to a reduction in mortality. It is difficult to find a detailed explanation for these differences in long-term prognosis after MI. The extrapolation after MI in the TRITON-TIMI 38 trial is based on other data sources where the long-term survival prognosis may have been worse compared with the present study. Possibly, the larger proportion of the reduction in MIs in the TRITON-TIMI 38 trial resulted from a reduction in procedure-related biomarker elevations, 23 which is now known to carry little consequences for long-term survival. 24 The costs per gained health outcome demonstrated with ticagrelor are comparable with those reported when clopidogrel in addition to ASA was evaluated against ASA alone in non-ST-elevation ACS patients. 25 The economic evaluations of an early invasive treatment strategy compared with a conservative strategy in patients with unstable coronary artery disease showed similar or higher cost-effectiveness ratios compared with the results of the present study.
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The PLATO study was designed to reflect the current clinical practice in which ticagrelor was administered early in the acute phase of the ACS episode and compared with a flexible loading dose of clopidogrel. This may contribute to the generalizability of the results to a setting where ticagrelor is actually implemented in clinical care. It should be pointed out that the base-case analysis used unit costs and data for extrapolation primarily from a Swedish setting. Several sensitivity scenarios indicate that the costeffectiveness results should be valid for other settings as well. When the costs and QALYs of the clinical pathways in the first year of the analysis were set equal for ticagrelor-and clopidogreltreated patients and at the same time applying a daily ticagrelor cost of E3 per day, the cost per QALY gained with ticagrelor (approximateley E7300) was below generally acceptable thresholds for cost-effectiveness. This analysis represents jurisdictions with a high cost of ticagrelor (E3) and where there is believed to be small differences in non-drug costs between ticagrelor-and clopidogrel-treated patients during the 12 months of therapy. Further sensitivity analyses indicated that the cost-effectiveness results are not sensitive to the estimated costs, quality-of-life and event risks required for extrapolation. The generalizability of the PLATO design to clinical practice together with the fact that the cost-effectiveness results appear robust to data sources that could potentially differ between countries imply that the the cost per QALY gained with ticagrelor should be below conventional thresholds for cost-effectiveness in most European settings.
Limitations
Regarding methodology, it should be pointed out that the current analysis took a health-care perspective, whereas a societal perspective is sometimes preferred for decision-making. The reason for applying a health-care perspective was to stay as close as possible to the PLATO study results and preserve internal validity of the findings. If a societal perspective is adopted, further assumptions regarding the occurrence and magnitude of non-health-care costs would have been required. In this particular case, non-health-care costs associated with cardiovascular events would have been included in the analysis. However, since ticagrelor reduces cardiovascular events, inclusion of further costs due to those events would likely enhance the findings of the present study.
It should also be pointed out that the drug prices applied in the present analysis are dynamic and may change. In the present analysis, a low generic clopidogrel price (E0.06 per day) was used, indicating that the results are not sensitive to a further reduction in the price of generic clopidogrel.
Conclusions
Based on the clinical and health-economic evidence from the PLATO study, treating ACS patients with ticagrelor for 12 months is associated with a cost per QALY below generally accepted thresholds for cost-effectiveness.
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Supplementary material is available at European Heart Journal online.
